## Edgar Filing: Valentine Karen - Form 4

Valantina Kar

Form 4												
April 28, 201 FORM Check thi if no long subject to Section 14 Form 4 or Form 5	Was CHAN	ITIES A hington, GES IN SECUR 5(a) of th	OMB APPROVAL OMB 3235-0287 Number: January 31, 2005 Estimated average burden hours per response 0.5									
obligatior may conti <i>See</i> Instru 1(b).	inue. Section 17(a			•	ding Con Compan	· ·		f 1935 or Sectio 40	n			
(Print or Type R	Responses)											
Valentine Karen S			2. Issuer Name <b>and</b> Ticker or Trading Symbol ANTIGENICS INC /DE/ [AGEN]					5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
(Mor				3. Date of Earliest Transaction (Month/Day/Year) 04/26/2010					Director 10% Owner X Officer (give title Other (specify below) below) VP and General Counsel			
			endment, Date Original onth/Day/Year)				<ul> <li>6. Individual or Joint/Group Filing(Check</li> <li>Applicable Line)</li> <li>_X_ Form filed by One Reporting Person</li> </ul>					
LEXINGTO	N, MA 02421							•	More than One Re			
(City)	(State)	(Zip)	Table	e I - Non-I	Derivative	Securi	ties Acc	quired, Disposed o	f, or Beneficial	ly Owned		
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)		Date, if	Code (Instr. 8)	4. Secur on(A) or D (D) (Instr. 3,	4 and (A) or	d of 5) Price	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
Common Stock	04/26/2010			A <u>(1)</u>	2,500	А	\$ 1.19	53,991	D			

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
 (e.g., puts, calls, warrants, options, convertible securities)

## Edgar Filing: Valentine Karen - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. ofNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		ate	Secur	ınt of rlying	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secu Bene Owne Follo Repo Trans (Instr
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

## **Reporting Owners**

Reporting Owner Name / Address	Relationships							
	Director	10% Owner	Officer	Other				
Valentine Karen C/O ANTIGENICS INC. 3 FORBES RD LEXINGTON, MA 02421			VP and General Cou	nsel				
Signatures								
Christine M. Klaskin, by Powe Attorney	r of	04/	04/28/2010					
<u>**</u> Signature of Reporting Person			Date					
Explanation of Responses:								

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Represents settlement of restricted stock awarded on January 26, 2010.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.